US · CARL · MEDICAL - DEVICES
Carlsmed, Inc. (CARL) intrinsic value and stock valuation
$17.42as of 2026-11-21 · Mkt cap 375.7M
Data updated · price as of 2026-11-21
- P/E
- Pro
- P/B
- Pro
- P/S
- Pro
Price history
Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.
Carlsmed, Inc. DCF and intrinsic value
InvestorsCraft values CARL with the Chepakovich two-stage DCF model — currently rated fairly valued. How the model works · Run your own DCF prefilled from CARL’s statements →
Carlsmed, Inc. Graham Number
The Graham Number is not defined for negative earnings or book value. Guide · Calculator →
How the business is doing
Fiscal 2023–2025, USD
Is it expensive?
Each multiple against its own 15-year range, or against peers where no history is available
Financials
Statements by fiscal year
| 2025 | 2024 | 2023 | |
|---|---|---|---|
| Revenue | $50.5M | $27.2M | $13.8M |
| Operating income | -$-30.57M | -$-24.12M | -$-18.59M |
| Net income | -$-29.63M | -$-24.26M | -$-18.9M |
| EPSd | -$-2.08M | -$-1.46M | -$-4.25M |
| Operating cash flow | -$-28.98M | -$-25.47M | -$-17.48M |
| Capital expenditure | -$-640K | -$-180K | -$-140K |
| Free cash flow | -$-29.62M | -$-25.65M | -$-17.61M |
| Total assets | $130.1M | $51.8M | $14M |
| Total debt | $17.4M | $17.2M | $11.4M |
| Net debt | -$-68.38M | -$-22.95M | $4.17M |
| Total equity | $98.9M | -$-70.63M | -$-46.13M |
| Cash and short-term investments | $109.8M | $40.1M | $7.22M |
Income statement
| 2025 | 2024 | 2023 | |
|---|---|---|---|
| Revenue | $50.5M | $27.2M | $13.8M |
| Cost of revenue | $12.5M | $7.12M | $3.88M |
| Gross profit | $38M | $20.1M | $9.9M |
| Research and development expenses | $17M | $14.3M | $7.39M |
| Selling, general and administrative expenses | $51.6M | $29.9M | $21.1M |
| Other expenses | $0.00 | $0.00 | $0.00 |
| Operating expenses | $68.6M | $44.2M | $28.5M |
| Cost and expenses | $81.1M | $51.3M | $32.4M |
| Interest income | $2.7M | $1.33M | $330K |
| Interest expense | $1.43M | $1.32M | $640K |
| Depreciation and amortization | $280K | $140K | $140K |
| Ebitda | -$-27.92M | -$-22.79M | -$-18.12M |
| Operating income | -$-30.57M | -$-24.12M | -$-18.59M |
| Total other income/expenses, net | $940K | -$-140K | -$-310K |
| Income before tax | -$-29.63M | -$-24.26M | -$-18.9M |
| Income tax expense | $0.00 | $0.00 | $0.00 |
| Net income | -$-29.63M | -$-24.26M | -$-18.9M |
| Weighted average shares outstanding | $14.2M | $16.6M | $4.45M |
| Weighted average diluted shares outstanding | $14.2M | $16.6M | $4.45M |
Balance sheet
| 2025 | 2024 | 2023 | |
|---|---|---|---|
| Cash and short-term investments | $109.8M | $40.1M | $7.22M |
| Net receivables | $11.4M | $6.77M | $3.17M |
| Inventory | $1.84M | $990K | $570K |
| Total current assets | $126.7M | $49.4M | $11.8M |
| Property, plant and equipment, net | $3.31M | $1.9M | $2.24M |
| Goodwill and intangible assets | $0.00 | $0.00 | $0.00 |
| Long-term investments | $0.00 | $0.00 | $0.00 |
| Total non-current assets | $3.45M | $2.47M | $2.26M |
| Total assets | $130.1M | $51.8M | $14M |
| Accounts payable | $4.48M | $2.41M | $1.69M |
| Short-term debt | $750K | $450K | $2.15M |
| Deferred revenue | $0.00 | $0.00 | $0.00 |
| Total current liabilities | $14.3M | $8.82M | $7.44M |
| Long-term debt | $16.7M | $16.7M | $9.24M |
| Deferred revenue, non-current | $0.00 | $0.00 | $0.00 |
| Total non-current liabilities | $17M | $113.6M | $52.7M |
| Capital lease obligations | $2.07M | $1.32M | $2.08M |
| Total liabilities | $31.3M | $122.5M | $60.2M |
| Common stock | $0.00 | $0.00 | $0.00 |
| Retained earnings | -$-100.81M | -$-71.17M | -$-46.91M |
| Accumulated other comprehensive income (loss) | $0.00 | $0.00 | $0.00 |
| Total equity | $98.9M | -$-70.63M | -$-46.13M |
| Total investments | $24M | $0.00 | $0.00 |
| Total debt | $17.4M | $17.2M | $11.4M |
| Net debt | -$-68.38M | -$-22.95M | $4.17M |
Cash flow statement
| 2025 | 2024 | 2023 | |
|---|---|---|---|
| Net income | -$-29.63M | -$-24.26M | -$-18.9M |
| Depreciation and amortization | $280K | $140K | $140K |
| Stock-based compensation | $1.93M | $250K | $120K |
| Change in working capital | -$-4.89M | -$-4.08M | -$-890K |
| Accounts receivable | -$-5.01M | -$-3.97M | -$-2.43M |
| Inventory | -$-2.69M | -$-1.8M | -$-910K |
| Accounts payable | $2.32M | $300K | $940K |
| Net cash provided by operating activities | -$-28.98M | -$-25.47M | -$-17.48M |
| Investments in property, plant and equipment | -$-640K | -$-180K | -$-140K |
| Acquisitions, net | $0.00 | $0.00 | $0.00 |
| Net cash used for investing activities | -$-25.48M | -$-180K | -$-140K |
| Common stock issued | $93.7M | $0.00 | $60K |
| Common stock repurchased | $0.00 | $0.00 | $0.00 |
| Dividends paid | $0.00 | $0.00 | $0.00 |
| Net cash used for financing activities | $100.1M | $58.5M | $3.18M |
| Net change in cash | $45.7M | $32.9M | -$-14.44M |
| Cash at end of period | $85.9M | $40.2M | $7.37M |
| Operating cash flow | -$-28.98M | -$-25.47M | -$-17.48M |
| Capital expenditure | -$-640K | -$-180K | -$-140K |
| Free cash flow | -$-29.62M | -$-25.65M | -$-17.61M |
Line items
Line items
Line items
About Carlsmed, Inc.
Carlsmed, Inc., a commercial-stage medical technology company, designs, manufactures, and markets AI-enabled personalized spine surgery solutions. The company develops aprevo, a comprehensive technology platform for spine fusion surgery procedures. Its aprevo platform includes proprietary surgical planning software, using outcomes-based algorithms that are aided with artificial intelligence, and resulting custom-built, anatomically designed vertebral interbody implants. The company was incorporated in 2018 and is based in Carlsbad, California.
- CEO
- Michael Cordonnier
- Employees
- 127
- Beta
- 1.77
Explore
Frequently asked questions
What is the intrinsic value of Carlsmed, Inc. (CARL)?
Carlsmed, Inc. (CARL) is currently fairly valued based on the InvestorsCraft IC model — IC value is within 20% of the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.
Is CARL undervalued?
CARL trades at a price of $17.42 (Nov 21, 2026): fairly valued — IC value is within 20% of the price.
How is the intrinsic value calculated?
InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.
How often is this page updated?
Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.